Literature DB >> 11095799

Infection with Parvovirus B19.

.   

Abstract

Human parvovirus B19 is common and widespread. Major manifestations of B19 infection are transient aplastic crisis, erythema infectiosum, hydrops fetalis, acute and chronic rheumatoid-like arthropathy and, in the immunocompromised host, chronic or recurrent bone marrow infection. Less common presentations include skin eruptions, isolated cytopenias, vasculitis, hepatitis, and neuropathies. Increasing awareness of the clinical manifestations of B19 infection makes parvovirus B19 an emerging virus. B19 may persist in healthy or immunocompromised individuals. B19 has been suggested as a candidate agent in rheumatic diseases.

Entities:  

Year:  1999        PMID: 11095799     DOI: 10.1007/s11908-999-0030-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  45 in total

1.  Aseptic meningitis caused by parvovirus B19.

Authors:  P R Koduri; S J Naides
Journal:  Clin Infect Dis       Date:  1995-10       Impact factor: 9.079

2.  Neuralgic amyotrophy due to parvovirus infection.

Authors:  D W Denning; A Amos; P Rudge; B J Cohen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-05       Impact factor: 10.154

3.  Chronic bone marrow failure due to persistent B19 parvovirus infection.

Authors:  G J Kurtzman; K Ozawa; B Cohen; G Hanson; R Oseas; N S Young
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

4.  The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells.

Authors:  K Ozawa; J Ayub; S Kajigaya; T Shimada; N Young
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

5.  Liver dysfunction caused by parvovirus B19.

Authors:  H Tsuda
Journal:  Am J Gastroenterol       Date:  1993-09       Impact factor: 10.864

6.  Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.

Authors:  N Frickhofen; J L Abkowitz; M Safford; J M Berry; J Antunez-de-Mayolo; A Astrow; R Cohen; I Halperin; L King; D Mintzer
Journal:  Ann Intern Med       Date:  1990-12-15       Impact factor: 25.391

7.  Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus.

Authors:  S Loizou; J K Cazabon; M J Walport; D Tait; A K So
Journal:  Arthritis Rheum       Date:  1997-01

8.  Parvovirus B19 infection in patients receiving cancer chemotherapy: the expanding spectrum of disease.

Authors:  J L Graeve; P A de Alarcon; S J Naides
Journal:  Am J Pediatr Hematol Oncol       Date:  1989

9.  Experimental parvoviral infection in humans.

Authors:  M J Anderson; P G Higgins; L R Davis; J S Willman; S E Jones; I M Kidd; J R Pattison; D A Tyrrell
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

10.  Human parvovirus B19-associated arthritis in children.

Authors:  J J Nocton; L C Miller; L B Tucker; J G Schaller
Journal:  J Pediatr       Date:  1993-02       Impact factor: 4.406

View more
  3 in total

1.  Visualization of the externalized VP2 N termini of infectious human parvovirus B19.

Authors:  Bärbel Kaufmann; Paul R Chipman; Victor A Kostyuchenko; Susanne Modrow; Michael G Rossmann
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

Review 2.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

3.  The structure of human parvovirus B19.

Authors:  Bärbel Kaufmann; Alan A Simpson; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.